Independent Study Shows LiveRamp’s Authenticated Traffic Solution Drives More Than 340% Return on Investment for Marketers
19.5.2021 15:30:00 EEST | Business Wire | Press release
LiveRamp® (NYSE: RAMP) the leading data connectivity platform, today announced its Authenticated Traffic Solution (ATS) has been adopted by hundreds of publishers, brands and platforms across the globe, including in the US, UK, France, Italy, Spain, Germany, Australia and Japan. More than 70 demand and supply platforms and over 400 publishers, including 70% of the Comscore 20 and 65% of the Comscore 50, have adopted ATS to offer marketers a more efficient way to reach their customers and measure campaign outcomes without third-party cookies or device identifiers.
“The digital industry is undergoing massive shifts with the end of third-party cookies and mobile device identifiers. We set out to create the neutral and interoperable infrastructure for this new era, and the incredible, worldwide adoption of ATS proves we’ve done just that,” said LiveRamp CEO Scott Howe. “Simply put, ATS places publishers and marketers in control of their data. It generates better results for marketers, higher yields for publishers and provides the opportunity for greater transparency. Over 100 brands use ATS, including clients through agency partnerships, and we expect this number only to grow.”
Publishers
Publishers are leveraging ATS to enable people-based inventory and improve monetization, including Microsoft Advertising, the world's second-largest publisher, which has seen a larger than 40% increase in CPMs on authenticated impressions. The breadth of ATS adoption across the globe reveals that a variety of publishers see LiveRamp’s solution as not only viable to their business, but vital in serving their unique, diverse audiences. Other notable publishers who have adopted ATS include: Realtor.com, CafeMedia, Tubi, and The McClatchy Company in the US; Dennis Publishing, eBay Classifieds Group UK, and IDG in the UK; Burda Community Network in Germany; and Cricket Australia, the first in-app publisher signed, among many others.
- "TV viewers are now well-integrated into streaming environments, which are fragmented across a wide variety of device platforms for advertisers. This makes the marketer's challenge of reaching and measuring a target audience multi-dimensional, and having a people-based identifier is important to ensure that advertising campaigns are relevant across channels and devices," commented Mark Rotblat, Chief Revenue Officer at Tubi. “LiveRamp helps enable authenticated, first-party relationships with our viewers so we can continue to deliver impactful experiences, at scale."
- “Becoming an early-adopter of LiveRamp’s ATS solution in Europe has only strengthened our relationship with our valued publisher partners,” added Mandy Schwab, Director Digital Media at Burda Community Network (BCN). “Since integrating LiveRamp’s ATS solution one year ago, we’ve enabled media brands to successfully unlock the opportunity to better monetize media inventory through privacy-conscious, people-based identity.”
- “Together with LiveRamp, we are putting power back in the hands of publishers,” said Paul Bannister, CSO of CafeMedia. “We’re enabling our thousands of media brands to grow revenue by activating first-party data in a safe and privacy-centric manner, without having to worry about data leakage, particularly because of LiveRamp’s robust publisher data control technology. Already, we’re seeing authenticated audiences generate much higher yields than when using third-party cookies.”
Brands
A new Forrester Consulting Total Economic Impact™ (TEI) study, commissioned by LiveRamp, found advertisers who use LiveRamp’s ATS can achieve 343% ROI over three years with payback within only six months of initial investment.
Worldwide, over 100 brands across verticals have already recognized the urgency to find an alternative to data deprecation, embracing ATS as a durable and valuable solution for seamless activation, measurement and attribution across display, mobile in-app, connected TV and OTT. Compared to campaigns using third-party cookies, marketers saw significant improvement with LiveRamp, including:
- 403% increase in travel bookings for a leading international hotel chain
- 85 - 95% Video Completion Rate (VCR) for a leading social health non-profit
- 84.3% average increase in sustained ROAS from multiple brands over the last year
Enabling hundreds of brand advertising campaigns in the first quarter of 2021 alone, ATS powers a people-based approach to connecting with audiences across all channels, making consumer interactions relevant, addressable and measurable. As brands and their agencies pivoted quickly during the past year, they turned to LiveRamp to activate segments within technology platforms and publishers to reach real people—not cookies or device IDs.
- “Even before the phasing out of third-party cookies, we have been leveraging alternative identifiers to deliver more relevant marketing and improve marketing outcomes, especially in online video campaigns as consumers increase time spent with video,” said Manuel Cimarosti, Director of Media Analytics & Data Strategy at Danone. “In the first test alone, ATS delivered a 4% increase in video completion rate on top of 40% more efficient cost metrics when compared to the cookie. These results are invaluable as we continue growing our first-party relationship with consumers across more touchpoints, and reinvest the savings to increase our reach.”
- “Our industry has reached a crossroads where we can move forward with a transparent, privacy-conscious approach to user authentication, or risk the same faults we saw with the cookie,” added Liane Nadeu, SVP and head of precision media and investments at Digitas North America. “Our advice to clients is to take advantage of the time left before third-party cookies leave the ecosystem, and test and invest in authenticated solutions that will maintain consumer trust moving forward.”
Platforms
Garnering widespread platform support since its entry into the marketplace, the identifier is live with all major global supply-side platforms, including Index Exchange, Magnite, OpenX, PubMatic, and most recently, Xandr. ATS is also live on all major demand-side platforms, such as Amobee, Beeswax, Criteo, MediaMath, Roku and The Trade Desk.
“ATS is designed to stand the test of time, conscious of future privacy regulation and ensuring consumers are offered a value exchange,” added Travis Clinger, LiveRamp SVP of addressability and ecosystem. “It’s indisputable that authentications translate into higher-value inventory and better performance. Those who adopt an authentication strategy now will gain a significant competitive advantage in replacing mobile IDs, cookies and other problematic identifiers that do not prioritize consumer privacy.”
More information about ATS may be found at liveramp.com/authenticated-traffic-solution.
About LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005270/en/
Contact information
Michelle Millsap on behalf of LiveRamp
liveramp@havasformula.com
619-857-2384
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
